Quote List Quote List

HANSOH PHARMA(03692.HK)

Event Tracking

Dec31

Hanson Pharma Grants Glenmark Exclusive License for Aumolertinib, Expands International Market Layout

07:02

Dec28

Hanson Pharma Signs License Agreement with Jiangsu Hengrui for SHR6508

12:11

Dec16

Glenmark Pharmaceuticals Ltd Secures Exclusive Rights to Aumolertinib from Hansoh Pharmaceutical

10:11

Hansoh Pharmaceutical's Wholly-owned Subsidiary Enters into Exclusive Licensing, Collaboration and Distribution Agreement for Amivantamab with Glenmark

10:04

Dec13

UBS Analyst Maintains Buy Rating on Hansoh Pharmaceutical

01:17

Dec11

Hanson Pharmaceutical Group Reports Strong Phase II Clinical Trial Results for RET Inhibitor Resencatinib

10:09

Schedules & Filings

Schedules

Filings

Oct30

Distribution Plan(CST)

Cash dividend 0.2316 HKD

Sep25

Distribution Plan(CST)

Cash dividend 0.2316 HKD

Sep22

Distribution Plan(CST)

Cash dividend 0.2316 HKD

View More

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change

View More